<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning — drugdevelopR-package • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning — drugdevelopR-package"><meta name="description" content="Plan optimal sample size allocation and go/no-go decision rules for phase II/III drug development programs with time-to-event, binary or normally distributed endpoints when assuming fixed treatment effects or a prior distribution for the treatment effect, using methods from Kirchner et al. (2016) doi:10.1002/sim.6624
 and Preussler (2020). Optimal is in the sense of maximal expected utility, where the utility is a function taking into account the expected cost and benefit of the program. It is possible to extend to more complex settings with bias correction (Preussler S et al. (2020) doi:10.1186/s12874-020-01093-w
), multiple phase III trials (Preussler et al. (2019) doi:10.1002/bimj.201700241
), multi-arm trials (Preussler et al. (2019) doi:10.1080/19466315.2019.1702092
), and multiple endpoints (Kieser et al. (2018) doi:10.1002/pst.1861
)."><meta property="og:description" content="Plan optimal sample size allocation and go/no-go decision rules for phase II/III drug development programs with time-to-event, binary or normally distributed endpoints when assuming fixed treatment effects or a prior distribution for the treatment effect, using methods from Kirchner et al. (2016) doi:10.1002/sim.6624
 and Preussler (2020). Optimal is in the sense of maximal expected utility, where the utility is a function taking into account the expected cost and benefit of the program. It is possible to extend to more complex settings with bias correction (Preussler S et al. (2020) doi:10.1186/s12874-020-01093-w
), multiple phase III trials (Preussler et al. (2019) doi:10.1002/bimj.201700241
), multi-arm trials (Preussler et al. (2019) doi:10.1080/19466315.2019.1702092
), and multiple endpoints (Kieser et al. (2018) doi:10.1002/pst.1861
)."></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.2</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles"><li><a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a></li>
    <li><a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><a class="dropdown-item" href="../articles/index.html">More articles...</a></li>
  </ul></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json"></form></li>
<li class="nav-item"><a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="GitHub"><span class="fa fab fa-github fa-lg"></span></a></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1>drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/v1.0.2-cran/R/drugdevelopR-package.R" class="external-link"><code>R/drugdevelopR-package.R</code></a></small>
      <div class="d-none name"><code>drugdevelopR-package.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>Plan optimal sample size allocation and go/no-go decision rules for phase II/III drug development programs with time-to-event, binary or normally distributed endpoints when assuming fixed treatment effects or a prior distribution for the treatment effect, using methods from Kirchner et al. (2016) <a href="https://doi.org/10.1002/sim.6624" class="external-link">doi:10.1002/sim.6624</a>
 and Preussler (2020). Optimal is in the sense of maximal expected utility, where the utility is a function taking into account the expected cost and benefit of the program. It is possible to extend to more complex settings with bias correction (Preussler S et al. (2020) <a href="https://doi.org/10.1186/s12874-020-01093-w" class="external-link">doi:10.1186/s12874-020-01093-w</a>
), multiple phase III trials (Preussler et al. (2019) <a href="https://doi.org/10.1002/bimj.201700241" class="external-link">doi:10.1002/bimj.201700241</a>
), multi-arm trials (Preussler et al. (2019) <a href="https://doi.org/10.1080/19466315.2019.1702092" class="external-link">doi:10.1080/19466315.2019.1702092</a>
), and multiple endpoints (Kieser et al. (2018) <a href="https://doi.org/10.1002/pst.1861" class="external-link">doi:10.1002/pst.1861</a>
).</p>
    </div>


    <div class="section level2">
    <h2 id="see-also">See also<a class="anchor" aria-label="anchor" href="#see-also"></a></h2>
    <div class="dont-index"><p>Useful links:</p><ul><li><p><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">https://github.com/Sterniii3/drugdevelopR</a></p></li>
<li><p><a href="https://sterniii3.github.io/drugdevelopR/">https://sterniii3.github.io/drugdevelopR/</a></p></li>
<li><p>Report bugs at <a href="https://github.com/Sterniii3/drugdevelopR/issues" class="external-link">https://github.com/Sterniii3/drugdevelopR/issues</a></p></li>
</ul></div>
    </div>
    <div class="section level2">
    <h2 id="author">Author<a class="anchor" aria-label="anchor" href="#author"></a></h2>
    <p><strong>Maintainer</strong>: Lukas D. Sauer <a href="mailto:sauer@imbi.uni-heidelberg.de">sauer@imbi.uni-heidelberg.de</a> (<a href="https://orcid.org/0000-0002-1340-9994" class="external-link">ORCID</a>)</p>
<p>Authors:</p><ul><li><p>Stella Erdmann <a href="mailto:erdmann@imbi.uni-heidelberg.de">erdmann@imbi.uni-heidelberg.de</a></p></li>
<li><p>Johannes Cepicka</p></li>
<li><p>Marietta Kirchner</p></li>
<li><p>Meinhard Kieser</p></li>
</ul></div>

  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Stella Erdmann, Johannes Cepicka, Marietta Kirchner, Meinhard Kieser, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer></div>





  </body></html>

